Skip to content

Study on the efficacy and mechanism of Zishen Yutai pills in the treatment of patients with endometriosis after laparoscopic operation

Study on the efficacy and mechanism of Zishen Yutai pills in improving oocyte quality and treating EMs infertility through anti-oxidative stress based on SIRT1 regulation of Nrf2/ARE pathway.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000507
Enrollment
Unknown
Registered
2024-10-01
Start date
2024-09-04
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

Placebo group:Placebo+Dydrogesterone tablets
Zishen Yutai pill group:Zishen Yutai pill+Dydrogesterone tablets

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Patients = 20 years old and =40 years old who met the diagnostic criteria for ovarian endometriosis and infertility and underwent laparoscopic excision of cysts; (2) Laparoscopic bilateral tubal fluidization showed that at least one tubal was patency; (3) preoperative menstrual cycle is basically normal (28±7 days) postoperative active preparation for pregnancy expecting pregnancy; (4) Able to sign informed consent and stable interviewers. Those who meet the above four criteria at the same time are included.

Exclusion criteria

Exclusion criteria: (1) Premature ovarian dysfunction with AMH < 0.5ng/mL after surgery; (2) male factors cause infertility; (3) Patients with a history of mental illness; (4) Patients with organic diseases of heart lung liver kidney and other important organs; (5) Allergic constitution or allergic to the drug under study; (6) Unwilling to cooperate for various reasons and unable to fully cooperate with the whole process researcher. Those who met any of the above criteria were not included in the study.

Design outcomes

Primary

MeasureTime frame
ROS;FSH;SIRT1;GSH-Px;LH;Nrf2;SOD;Pregnancy condition;Number of basal sinus follicles;anti-Mullerian hormone(AMH);

Secondary

MeasureTime frame
NF-kB;VAS;Ovarian volume;P62;

Countries

China

Contacts

Public ContactPei Fangli

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

374496250@gq.com13580483429

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026